# Robert Nelsen

> Robert Nelsen is a Series B investor at ARCH Venture Partners backing Biotechnology. See 96 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners)
- Location: New York, United States
- Total investments: 96
- Last investment: Aug 2026
- Lead investor: 35%
- Last updated: Aug 2026
- X (Twitter): http://twitter.com/rtnarch

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN);Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $15M–$216M |
| Series B | $25M–$200M |
| Series C | $31M–$205M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 35 | 36% |
| Health Care | 26 | 27% |
| Therapeutics | 12 | 13% |
| Pharmaceutical | 11 | 11% |
| Medical | 9 | 9% |

44 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 30 | 31% |
| Series A | 29 | 30% |
| Series C | 12 | 13% |
| Seed | 5 | 5% |
| Series D | 3 | 3% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 46 | 48% |
| China | 2 | 2% |
| Israel | 1 | 1% |
| United Kingdom | 1 | 1% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M | Series E | Aug 06, 2026 |  |
| Trase | Trase provides and implements complete AI agent solutions, allowing businesses to automate complicated administrative procedures and operations in a safe and secure manner. | $107M | Seed | Jun 24, 2026 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |
| Paradigm | Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $78M | Series B | Dec 04, 2025 |  |
| SciNeuro | SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases. | $53M | Venture - Series Unknown | Dec 04, 2025 |  |
| Dispatch Bio | Dispatch Bio helps create a world where all cancer patients can be cured. | $216M | Series A | Jul 23, 2025 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. | $92M | Series C | Jan 15, 2025 |  |
| Be Biopharma | Be Biopharma is developing B cells as medicines. | $82M | Venture - Series Unknown | Oct 22, 2024 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $135M | Series A | Oct 08, 2024 |  |
| Stability AI | Stability AI is an artificial intelligence-driven visual art startup that designs and implements open AI tools. The company focuses on creating open models for various media types, including image, video, 3D, and audio, with applications also targeting enterprise-level needs. Stability AI fosters a vibrant community involving experts and partnersworldwide, enhancing collaboration in developing AI tools. | $80M | Venture - Series Unknown | Jun 25, 2024 |  |

10 of 96 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 22 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 19 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 14 deals together
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 9 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 9 deals together
- [Bezos Expeditions](https://shizune.co/investors/profile/bezos-expeditions) — VC Fund, 8 deals together

## About ARCH Venture Partners

VC Fund · Chicago, United States

ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture fundstotaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

5 contacts available at ARCH Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Cindy Bayley | Affiliate | https://shizune.co/investors/profile/cindy-bayley |
| Clinton Bybee | Co-Founder and Managing Director | https://shizune.co/investors/profile/clinton-w-bybee |
| Hong Hou | Venture Partner | https://shizune.co/investors/profile/hong-hou |
| Keith Crandell | Co-founder & Managing Director | https://shizune.co/investors/profile/keith-l-crandell |
| Kristina Burow | Managing Director | https://shizune.co/investors/profile/kristina-burrow |

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors in Israel](https://shizune.co/investors/health-care-angel-investors-israel)
- [Mobile Apps Angel Investors in Israel](https://shizune.co/investors/mobile-apps-angel-investors-israel)
- [Sporting Goods Angel Investors in United States](https://shizune.co/investors/sporting-goods-angel-investors-united-states)
- [Health Care Angel Investors in Middle East](https://shizune.co/investors/health-care-angel-investors-middle-east)
- [Sporting Goods Angel Investors](https://shizune.co/investors/sporting-goods-angel-investors)
- [Mobile Apps Investors in Israel](https://shizune.co/investors/mobile-apps-investors-israel)

## FAQ

### What does Robert Nelsen invest in?

Robert Nelsen invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 96 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Robert Nelsen's check size?

Robert Nelsen typically joins rounds of $15M–$216M at Series A, $25M–$200M at Series B and $31M–$205M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Robert Nelsen participates in.

### When did Robert Nelsen last invest?

The most recent investment recorded for Robert Nelsen closed in Aug 2026. Shizune tracks 96 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co